Boothbay Fund Management LLC Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Boothbay Fund Management LLC trimmed its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 21.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,890 shares of the company's stock after selling 27,943 shares during the quarter. Boothbay Fund Management LLC owned 0.21% of Enliven Therapeutics worth $2,360,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Barclays PLC boosted its stake in Enliven Therapeutics by 295.8% in the 3rd quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after purchasing an additional 42,012 shares in the last quarter. Geode Capital Management LLC raised its holdings in Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock worth $19,164,000 after buying an additional 67,813 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock worth $5,892,000 after buying an additional 6,611 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Enliven Therapeutics by 15.3% during the fourth quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock valued at $1,821,000 after buying an additional 10,746 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Enliven Therapeutics during the third quarter valued at approximately $559,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright upped their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 21st.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company's stock, valued at approximately $265,330. The trade was a 20.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,751 shares of company stock valued at $1,331,288 in the last 90 days. Company insiders own 29.20% of the company's stock.

Enliven Therapeutics Stock Up 3.3 %

Shares of Enliven Therapeutics stock traded up $0.66 during trading hours on Friday, reaching $20.51. 221,177 shares of the stock traded hands, compared to its average volume of 259,995. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -10.79 and a beta of 1.03. The company has a 50 day moving average price of $19.17 and a 200 day moving average price of $22.38.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.